DAVID J. GRAINGER - 01 Nov 2021 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role
Chief Innovation Officer
Signature
/s/ Marella Thorell, attorney-in-fact
Issuer symbol
CNTA
Transactions as of
01 Nov 2021
Transactions value $
$0
Form type
4
Filing time
02 Nov 2021, 19:00:29 UTC
Previous filing
08 Oct 2021
Next filing
01 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CNTA Share Option (right to buy) Award $0 +175K $0.00 175K 01 Nov 2021 Ordinary Shares 175K $14.01 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to such option shall vest and become exercisable on November 1, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.
F2 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.